Loading the records…
Loading the records…
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH NIAID
National Institutes of Health is planning to buy "AUTOIMMUNE DISEASES STATISTICAL & CLINICAL COORDINATING CENTER (AD-SCCC)". This is an early notice: it is not taking bids yet. The work is in Durham, NC, USA. Responses are due Dec 1, 2026. In the last 2 years, similar work went to 10 or more companies, usually for about $8.9M per award. An award is expected between December 2027 and March 2028.
Put together from the facts on this page; the details and sources are below.
Your briefs and their views: My briefs.
Every notice posted under solicitation 75N93026R00009 in this department, oldest first.
Standard steps for the notice type; not advice about this buyer.
gnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Allergy, Immunology, and Transplantation (DAIT) has a requirement to support a broad range of services critical for the design, development, execution, and analysis of clinical research in autoimmune diseases. The major clinical research programs to be supported by this solicitation include, Autoimmunity Centers of Excellence and Immune Tolerance Network (ACE), as well as investigator initiated clinical trials (IICT), and other clinical trials or study activities supported by NIAID herein collectively referred to as NIAID supported research. Description Topic Title: Autoimmune Diseases Statistical & Clinical Coordinating Center (ADSCCC) The Division of Allergy, Immunology, and Transplantation (DAIT), National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), project is for work related to the contract below: �Autoimmune Diseases Statistical & Clinical Coordinating Center (AD-SCCC)�, RHO Federal Systems Division, Inc. (Contract 75N93022C00003) This contract was awarded on a competitive basis for a five-year period from February 1, 2022 through January 31, 2027. A term type/level of effort contract was awarded for the delivery of 56,170 direct labor hours per year for Years 1-5. The total value of the contract is $49,268,667 and includes options for extension of the term for a total performance period of 5 years and options for increases in the level of effort, with the purpose of establishing an Autoimmune Diseases Statistical & Clinical Coordinating Center (AD- SCCC) that will provide a broad range of support critical for the design, development, execution, and analysis of clinical research sponsored by NIAID in autoimmune diseases and diseases related to mucosal immunology and primary immune deficiencies. The scope of clinical research to be supported by the AD- SCCC includes: (i) clinical trials at all phases to evaluate the safety and efficacy of investigational products and innovative approaches for disease treatment and prevention; (ii) studies of underlying mechanisms as integral components of clinical trials; (iii) clinical studies (e.g., genetic studies, microbiome studies, surveys of current therapies, etc.); and (iv) surrogate/biomarker studies. The scope of statistical and clinical support functions to be performed by the AD-SCCC includes statistical design and analysis; protocol development; study initiation and management; clinical safety and pharmacovigilance support; safety oversight; management of clinical study collaboration portals; manuscript preparation and management of sample repositories. The NIAID, NIH, conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. The causes, pathogenesis, diagnosis, treatment, and prevention of autoimmune diseases are major areas of emphasis for NIAID�s Division of Allergy, Immunology, and Transplantation (DAIT). DAIT pursues research on autoimmune diseases by supporting investigator-initiated research projects, cooperative clinical studies, national networks of research centers, and demonstration and education research projects. A critical component of the Division�s mission focuses on clinical research to develop new and/or improved strategies to treat or prevent autoimmune diseases through rigorous evaluations of the safety and efficacy of investigational products and therapeutic interventions, studies to elucidate underlying mechanisms of disease, studies to develop and evaluate surrogate/biomarkers of disease stage, severity and progression, and clinical studies of disease natural history. The purpose of this acquisition is to extend the period of performance of the current contract (through July 31, 2028), beginning February 1, 2027, thereby maintaining the same direct labor hours to maintain ongoing clinical trial operations while DAIT completes the competition under the Clinical Data, Safety, and Coordinating Centers (CDSCC) NOFO. The extension retains the existing scope and contract type. The required research and development clinical trial activities are severable in nature, the 18-month extension will be structured as two discrete option periods. Specifically, the Contractor will be responsible for the following: A. Statistical Design Provide expertise, advice and assistance pin the development of statistical design plans for the development of concept and full study proposals for NIAID supported clinical research; Provide assistance in the preparation of concept and full proposals and study-specific protocols; Provide assistance in the preparation of concept and full proposals and protocols for mechanistic studies; Provide support for preclinical safety study evaluation by providing statistical expertise for, and participate in, evaluating the accuracy and validity of data from preclinical safety studies in support of clinical trials if applicable; Provide assistance for clinical trials and mechanistic studies post-study initiation. B. Statistical Analysis Development and preparation of the Statistical Analysis Plan (SAP) for each clinical trial in conjunction with the Study Management Teams (SMTs); Preparation of interim and final analyses; Preparation of summary data reports; Development and preparation of results for posting as required by ClinicalTrials.gov; Review of the accuracy and completeness of statistical data and data analyses for all abstracts, manuscripts, and presentations reporting on the clinical studies conducted by the relevant NIAID-sponsored networks and investigators prior to presentation or submission for publication. Collaboration with NIAID-supported research, including the NIAID Clinical Data and Safety Management Center (CDSMC); C. Protocol Development and Study Initiation Provide expert advice and assistance to SMTs in the development of protocols for clinical trials and mechanistic studies; Provide expert advice, assistance and coordination in the preparation, writing, review and approval of protocol-related documents and materials in collaboration with NIAID, SMTs, and the CDSMC and other NIAID supported research. D. Data Management and Reporting E. Clinical Safety and Pharmacovigilance Center Support F. Safety Oversight Structure Support G. Clinical Study Internet-Based Collaboration Portals H. Training I. Repository of Biological Specimens J. Other Technical and Administrative Support K. Scientific and Technical Personnel L. Facilities, Equipment and Other Resources M. Quality Assurance/Quality Control N. Overall Project Management O. Initial and Final Transitions The NIAID intends to negotiate, under the authority of RFO - FAR Part 6.302-1 and HHSAR Part 306.302-1, on a sole source basis with Rho, to modify the existing contract to extend the current contract by a total of 18-months [Term Option 5 (12-months, February 1, 2027 through January 31, 2028), and Term Option 6 (6-months, February 1, 2028 through July 31, 2028)]. Due to the complex nature of DAIT clinical trial operations and the need for a contractor to perform the required AD-SCCC services during the interim period, the requirement is to maintain support for the existing portfolio without an interruption in protocol operations, statistical support, dat
19 award notices on SAM.gov in the last 24 months. Matched by: Same office (NATIONAL INSTITUTES OF HEALTH NIAID), same product/service code (PSC) AN12 and NAICS 541715.
Single-winner award sizes (11): middle half $2.1M to $24.6M, median $8.9M; range $10K to $32.9M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| EMINENT SERVICES CORP | 1 | $32.9M | Mar 30, 2026 |
| DUKE UNIVERSITY Durham NC 27705 USA | 1 | $28.3M | Mar 31, 2025 |
| Quality Biological, Inc | 1 | $25.4M | Apr 9, 2025 |
| ARISAN THERAPEUTICS INC | 1 | $23.9M | Aug 3, 2026 |
| UNIVERSITY OF TENNESSEE Memphis TN 38103 USA | 1 | $9.3M | Aug 3, 2026 |
| ZEPTO LIFE TECHNOLOGY, INC. | 1 | $8.9M | Jul 17, 2026 |
| FLUID DISCOVERY, INC. | 1 | $2.6M | Aug 29, 2025 |
| BAEBIES, INC. | 1 | $2.3M | Aug 29, 2025 |
| NEOVAXSYN INC | 1 | $2.0M | Jan 14, 2025 |
| MOLECULAR EXPRESS, INC | 1 | $2.0M | Jan 14, 2025 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Notices whose amount is a placeholder such as $999,999,999 are not added in. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
None of these past winners filed lobbying reports naming Natl Institutes of Health (NIH) since 2024. No sign of an incumbent lobbying push at this agency.
No lobbyist on these filings lists a past Natl Institutes of Health (NIH) job: no revolving-door tie found in these filings. (These are lobbyists the companies pay, not their own staff.)
None of these winners matched a listed company, so PAC and FARA checks did not run.
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
No bills named on these filings under National Institutes of Health-related issues.
A bill's title is shown only when the filing's own text names it; filings often cite last Congress's bill numbers.
No rules or proposed rules from the department in the last 12 months.
No executive order in the last 12 months names National Institutes of Health in its title or summary.
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
None of the past winners matched a listed company.
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.